The first generation of mAbs, unveiled in 1975 (ref. 1), were murine mAbs derived from mouse B-cell hybridomas (see “Monoclonal antibodies by design”). However, as murine mAbs moved into ...

Sponsored content brought to you by In the rapidly advancing field of immuno-oncology research, there has been increasing ...

These engineered antibodies can convert proteins from a threat recognition agent, into a disease-fighting form. Transgenic mice allow researchers to create “humanized” mice with human equivalents of ...

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B ...

Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized ...

Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...

Data were summarized with the search of 'colorectal' and 'antibody' as of August 2012 at ClinicalTrials.gov [202]. EGFR: EGF receptor; mAb: Monoclonal antibody; VEGFR: VEGF receptor. The authors ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution ...

a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre ...